当前位置:首页 - 行情中心 - 瑞康医药(002589) - 财务分析 - 利润表

瑞康医药

(002589)

  

流通市值:31.96亿  总市值:41.38亿
流通股本:11.62亿   总股本:15.05亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入6,105,062,530.674,079,932,498.772,073,027,669.1612,311,277,753.66
营业收入6,105,062,530.674,079,932,498.772,073,027,669.1612,311,277,753.66
二、营业总成本6,210,217,250.064,183,994,764.222,081,916,966.4712,623,185,403.65
营业成本5,286,626,511.543,546,769,335.881,753,394,409.5810,639,203,031.03
税金及附加37,264,388.2317,362,677.029,464,728.6752,127,203
销售费用375,533,520.33259,367,477.51102,338,007.79847,149,084.1
管理费用334,883,448.28219,247,951.7494,926,386.03699,910,167.24
研发费用10,177,007.276,264,217.062,846,655.1422,677,647.78
财务费用165,732,374.41134,983,105.01118,946,779.26362,118,270.5
其中:利息费用247,760,196.17167,607,654.66122,639,152.6407,706,194.55
其中:利息收入101,485,700.5353,314,073.7223,538,52783,968,621.89
加:公允价值变动收益-277,419,700-179,378,500-32,640,000-431,035,064.94
加:投资收益416,512,053.59318,348,963.2953,288,290.22-481,117,776.77
资产处置收益2,743,010.052,717,112.32,668,716.19-995,306.25
资产减值损失(新)----217,643,377.75
信用减值损失(新)12,904,000.8425,803,409.7716,451,497.77-290,820,250.37
其他收益1,519,481.151,403,263.082,098,533.8416,900,168.35
营业利润平衡项目0000
四、营业利润51,104,126.2464,831,982.9932,977,740.71-1,716,619,257.72
加:营业外收入4,615,394.742,987,364.681,192,715.931,107,371.14
减:营业外支出22,458,728.82714,931.11,233,874.9528,399,677.43
利润总额平衡项目0000
五、利润总额33,260,792.1667,104,416.5732,936,581.69-1,743,911,564.01
减:所得税费用5,428,772.5625,517,984.822,953,133.65-4,438,910.58
六、净利润27,832,019.641,586,431.7529,983,448.04-1,739,472,653.43
持续经营净利润27,832,019.641,586,431.7529,983,448.04-1,739,472,653.43
归属于母公司股东的净利润19,220,119.0630,667,269.8121,159,565.23-1,831,651,850.3
少数股东损益8,611,900.5410,919,161.948,823,882.8192,179,196.87
(一)基本每股收益0.010.020.01-1.24
(二)稀释每股收益0.010.020.01-1.24
九、综合收益总额27,832,019.641,586,431.7529,983,448.04-1,739,472,653.43
归属于母公司股东的综合收益总额19,220,119.0630,667,269.8121,159,565.23-1,831,651,850.3
归属于少数股东的综合收益总额8,611,900.5410,919,161.948,823,882.8192,179,196.87
公告日期2023-10-312023-08-302023-04-292023-04-29
审计意见(境内)标准无保留意见
TOP↑